Business Wire

Tetrate Adds Istio and Envoy Support for Arm Neoverse

Share

Tetrate, founded by creators and maintainers of Istio and Envoy, today announced that Istio service mesh and Envoy proxy now support the Arm® Neoverse™ platform. Arm is the leading technology provider of processor IP and its designs have enabled more than 215 billion chips. Neoverse support enables widely used open source software projects to run faster, with less energy usage and lower total cost of ownership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005425/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A simple service mesh as shown in Tetrate Service Bridge. (Graphic: Business Wire)

Neoverse is available on a wide range of cloud environments and for large-scale data center environments. Neoverse implementations include AWS Graviton2 processor-based Elastic Compute Cloud (Amazon EC2) instances, which offer a price/performance improvement of up to 40% over comparable x86-based instances.

“The diversity of applications is rapidly changing, and Arm is addressing the growing need for increased performance to take on compute-intensive workloads like service mesh,” said Bhumik Patel, director of ecosystem development, Infrastructure Line of Business, Arm. “By partnering with Tetrate to add Istio and Envoy support to Neoverse based platforms, we can bring better application performance, reduced energy consumption and lower TCO to customers of this industry-leading service mesh software.”

Neoverse is particularly well suited for complex workloads such as machine learning, AI, and now, service mesh. For example, AWS previewed Amazon EC2 instances powered by next-generation AWS Graviton3 processors, which will provide up to 25% better performance for compute-intensive workloads compared to current generation instances powered by Graviton2. AWS Graviton3 processors will deliver up to 2x higher floating-point performance for scientific and machine learning workloads, and will provide 50% higher memory bandwidth versus Graviton2-based instances to improve the performance of memory-intensive applications like scientific computing.

“We at Tetrate are seeing larger and more complex service mesh deployments that demand innovative solutions for meeting SLAs cost-effectively from edge to the cloud,” said Saptak Sen, vice president of Strategic Alliances at Tetrate. “We are proud to work with Arm, AWS, and the rest of the Envoy and Istio communities to help our customers in government, finance, ecommerce, and other markets make their mesh implementations more consistent, flexible, and scalable.”

Why Faster Performance is Important for Service Mesh

A service mesh is made up of microservices software instances which are created and destroyed to meet the capacity needs of an application at runtime. Each service instance is accompanied by a proxy instance, and messages between services are routed through the proxy instances.

Each message between services, or between services and the control plane, is authenticated, authorized, and encrypted/decrypted, boosting security. All of this work is compute-intensive, and encryption and decryption in particular are numerically intensive. Faster performance from the underlying hardware infrastructure can make a tremendous difference in the responsiveness of the service mesh.

Istio is the leading service mesh, and Istio software includes an extended version of the Envoy proxy. Tetrate is optimizing Istio and the Envoy proxy for performance. Neoverse supports these efforts and gives a solid boost to Istio and Envoy performance. Accelerating these software projects also yields higher performance when running Tetrate’s industry-leading service mesh management software, Tetrate Service Bridge.

How Istio Service Mesh Delivers for Government and Industry

Istio service mesh, accelerated by Arm Neoverse on multiple platforms, supports a number of benefits important to government and industry:

  • Security. Service mesh performs authentication, authorization, and encryption/decryption on every communication among service instances and with the control plane, enhancing security. Neoverse speeds the necessary processing, including numerical processing for encryption and decryption.
  • Agility. Service mesh supports rapid software development using continuous integration/continuous delivery (CI/CD) approaches. Neoverse provides a platform for accelerated performance, which can be managed and enhanced across software updates.
  • Business continuity. With service mesh, architects can create applications that can fail over from on-premises to cloud, from one availability zone in the cloud to another, and even from one cloud to another. Neoverse support is available on all these platforms, giving applications consistent performance optimization across all deployment targets.

Download Arm-Ready Versions of Istio

Those interested can download Arm-ready versions of Istio from Tetrate Labs. Options include a FIPS version, compliant with Federal Information Processing Standard (FIPS) 140-2, Security Requirements for Cryptographic Modules. And the number of options for accessing Istio running on Neoverse across multiple platforms is large and growing. To learn more, contact Tetrate.

About Arm

Arm technology is at the heart of a computing and data revolution that is transforming the way people live and businesses operate. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 215 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners we are at the forefront of designing, securing and managing all areas of AI-enhanced connected compute from the chip to the cloud.

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Annie Fink, Bospar
Annie@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 16:00:00 EEST | Press release

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number:e16102 Abstract Title: Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop

FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 14:38:00 EEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 10:00:00 EEST | Press release

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser

Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 10:00:00 EEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma27.5.2022 00:25:00 EEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom